diaDexus, an in-vitro diagnostic (IVD) company, has received the US Food and Drug Administration (FDA) marketing clearance for the automated version of its proprietary PLAC Test.
The PLAC Test product format, based on turbidimetric immunoassay (TIA) technology, is designed to run on most clinical chemistry analyzers, expanding the number of clinical labs and physician offices that are able to offer the PLAC Test.
diaDexus president and CEO Patrick Plewman said that they are pleased to have this format of their PLAC Test cleared by the FDA.
"The new automated TIA version addresses the heterophilic interference found in the previous version. We expect to launch the new version of the PLAC Test next quarter," Plewman said.